Prince, H Miles
Kim, Youn H
Horwitz, Steven M
Dummer, Reinhard
Scarisbrick, Julia
Quaglino, Pietro
Zinzani, Pier Luigi
Wolter, Pascal
Sanches, Jose A
Ortiz-Romero, Pablo L
Akilov, Oleg E
Geskin, Larisa
Trotman, Judith
Taylor, Kerry
Dalle, Stephane
Weichenthal, Michael
Walewski, Jan
Fisher, David
Dréno, Brigitte
Stadler, Rudolf
Feldman, Tatyana
Kuzel, Timothy M
Wang, Yinghui
Palanca-Wessels, Maria Corinna
Zagadailov, Erin
Trepicchio, William L
Zhang, Wenwen
Lin, Hui-Min
Liu, Yi
Huebner, Dirk
Little, Meredith
Whittaker, Sean
Duvic, Madeleine
Trotman, Judith
Joske, David
Prince, H. Miles
Taylor, Kerry
Lewis, Ian D.
Jonak, Constanze
Trautinger, Franz
Bechter, Oliver
Wolter, Pascal
Bron, Dominique
de Lima, Vladmir Claudio C.
Sanches, Jose Antonio Junior
Klasa, Richard
Bagot, Martine
Beylot-Barry, Marie
Dalle, Stephane
D'Incan, Michel
Dreno, Brigitte
Grange, Florent
Nicolay, Jan
Stadler, Rudolf
Weichenthal, Michael
Wobser, Marion
Assaf, Chalid
Loquai, Carmen
Quaglino, Pietro
Spina, Michele
Zinzani, Pier Luigi
Bosi, Alberto
Fattori, Pier Paolo
Grzanka, Aleksandra
Walewski, Jan
Lopez-Hernandez, Andres
Ortiz-Romero, Pablo L.
Roca, Jose Juan Rifon
Canales, Silvana Novelli
Dummer, Reinhard
Illidge, Timothy
Johnson, Rod
Whittaker, Sean
Morris, Stephen
McKay, Pam
Scarisbrick, Julia
Duvic, Madeleine
Feldman, Tatyana
Akilov, Oleg
Geskin, Larisa
Horwitz, Steve
Kim, Youn H.
Pro, Barbara
Kuzel, Timothy
Lerner, Adam
Eradat, Herbert
Sokol, Lubomir
Fisher, David C.
Hughey, Sarah
This article is maintained by: Elsevier
Article Title: Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
Journal Title: The Lancet
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S0140-6736(17)31266-7
CrossRef DOI link to the associated document: https://doi.org/10.1016/S0140-6736(17)31473-3
Content Type: article
Copyright: © 2017 Elsevier Ltd. All rights reserved.